Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Diane Brady

How GoodRx CEO Wendy Barnes is trying to halve the cost of GLP-1 obesity drugs

(Credit: Photo courtesy of GoodRx)
  • In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes.
  • The big story: Trump, Putin, and Zelensky headed for “Trilat”.
  • The markets: Flat or down.
  • Plus: All the news and watercooler chat from Fortune.

Good morning. I know several people on GLP-1 drugs. Some transformed their health; one used it to shed 10 pounds nobody thought she needed to lose. Such drugs have become the fastest-growing segment of drug spending, accounting for 10.5% of employers’ average pharmacy costs so far this year, vs. 8.9% in 2024. That’s up from 6.9% in 2023, when Americans spent $71.7 billion on such drugs. On average, employers pay between $8,000 and $10,000 per user each year for these drugs through healthcare plans.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.